Search results
Results from the WOW.Com Content Network
End stage pulmonary disease (ESPD) [2] is the result of chronic progressive lung diseases like COPD, [3] idiopathic pulmonary fibrosis, or systemic progressive diseases that affect the lungs such as cystic fibrosis or granulomatosis with polyangiitis. It is defined as when the lungs can no longer or barely remove enough carbon dioxide or supply ...
Certain medications like pirfenidone or nintedanib may slow the progression of the disease. [2] Lung transplantation may also be an option. [1] About 5 million people are affected globally. [8] The disease newly occurs in about 12 per 100,000 people per year. [4] Those in their 60s and 70s are most commonly affected. [4]
Lung transplantation is the only therapeutic option available in severe cases. A lung transplant can improve the patient's quality of life. [30] Immunosuppressive drugs can also be considered. These are sometimes prescribed to slow the processes that lead to fibrosis. Some types of lung fibrosis respond to corticosteroids, such as prednisone. [29]
Respiratory failure is classified as either Type 1 or Type 2, based on whether there is a high carbon dioxide level, and can be acute or chronic. In clinical trials, the definition of respiratory failure usually includes increased respiratory rate, abnormal blood gases (hypoxemia, hypercapnia, or both), and evidence of increased work of breathing.
When associated with significant airflow limitation, emphysema is a major subtype of chronic obstructive pulmonary disease (COPD), a progressive lung disease characterized by long-term breathing problems and poor airflow. [10] [11] Without COPD, the finding of emphysema on a CT lung scan still confers a higher mortality risk in tobacco smokers ...
Although Irwin and Rippe cautioned in 2005 that the use of "multiple organ failure" or "multisystem organ failure" should be avoided, [1] both Harrison's (2015) and Cecil's (2012) medical textbooks still use the terms "multi-organ failure" and "multiple organ failure" in several chapters and do not use "multiple organ dysfunction syndrome" at all.
Five-year survival rates can be used to compare the effectiveness of treatments. Use of five-year survival statistics is more useful in aggressive diseases that have a shorter life expectancy following diagnosis, such as lung cancer, and less useful in cases with a long life expectancy, such as prostate cancer.
It is life-threatening in the elderly or those who are immunocompromised. [ 13 ] [ 14 ] The most common treatment is antibiotics and these vary in their adverse effects and their effectiveness. [ 13 ] [ 15 ] Pneumonia is also the leading cause of death in children less than five years of age in low income countries. [ 15 ]